Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2018 01:01 ET | Source: Polyphor Ltd

Polyphor Ltd: U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin

Allschwil, Switzerland, April 19, 2018 U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy...